Brief: Allakos Announces First Patient Dosed In Phase 1 Trial Of Ak006 In Chronic Spontaneous Urticaria
28/05/2024 12:03
May 28 (Reuters) - Allakos Inc ALLK.O :
* ALLAKOS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF
AK006
IN CHRONIC SPONTANEOUS URTICARIA
* ALLAKOS INC - TOP-LINE PHASE 1 CSU RESULTS EXPECTED AT
YEAR END
2024
Source text for Eikon: ID:nGNX6Fw9Pg
Further company coverage: ALLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allakos
See all newsAllakos Inc reports results for the quarter ended March 31 - Earnings Summary
Allakos Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group
Allakos soars on buyout deal with Concentra Biosciences
Brief: Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences